Document:

Exhibit 10.1

 

 

 

November 28, 2022

 

Erin Darakjian

Chief Accounting Officer

Interim Chief Financial Officer

 

Dear Erin,

 

We are pleased to extend an interim pay agreement for your
work as P3’s Interim CFO and in your continued role as Chief Accounting Officer. You are a trusted and highly valued leader of our
P3 family, and your contributions are directly connected to the company’s growth and success. The following are the terms of our
interim pay agreement:

 

Lump Sum Payment: You
will receive a lump sum payment representing both salary and bonus award in line with the interim CFO role of $50,000 (fifty thousand
dollars) to be paid in the first pay period in December. This is in addition to your current salary and bonus plan as Chief Accounting
Officer. If your interim appointment extends beyond February 1, 2023, in consideration of your service as Interim Chief Financial Officer,
P3 will compensate you an additional lump sum of $50,000 – the first payment to be made in the first pay period of February 2023.
Additional payments will be made and every three (3) months thereafter - until a permanent Chief Financial Officer commences employment.

 

Annual Incentive: Your
target bonus will permanently increase to 50% of your base salary while you are in your role as Chief Accounting Officer. This bonus is
based on a combination of the Company’s and your performance with respect to target goals and metrics, subject to Board of Directors
approval each year. For the bonus related to fiscal year 2022, P3 will guarantee a bonus payout at 100% of target, without proration.
Going forward, so long as you remain an employee of P3, your bonus target will be 50% of your salary.

 

One-Time Equity Grant:
P3 shall grant to a non-qualified option to purchase 100,000 shares of P3’s Class A common stock (the “Stock Option”),
subject to your continued employment with P3 through the vesting date. The Stock Option shall have an exercise price per share equal to
the Fair Market Value on the grant date (as defined in the 2021 P3 Health Partners Inc. Incentive Award Plan (the “Plan”))
and shall have an outside expiration date of ten years from the grant date and will vest at 25% per year over a four year period (25%
per year commencing on October 18, 2023, the first anniversary of your appointment to the Interim CFO role).

 

     

     

    

 

 

 

I
sincerely appreciate your hard work, dedication, and leadership to P3 Health Partners. I look forward to your continued growth within
in the organization.

 

	Sincerely,	 
	 	 
	/s/ Sherif Abdou, M.D.	 
	Sherif Abdou, MD, MMM, FACP, FACPE	 
	Chief Executive Officer	 

 

I agree to the terms stipulated and indicate my acceptance
by signing and returning this document via DocuSign.

 

	 	Date:	11/28/2022
	 	 	 
	 	Signed:	/s/ Erin DarakjianExhibit 10.2

 

 

 

November 27, 2022

 

Atul Kavthekar

3407 Fairmont Avenue

Naperville, IL 60564

 

Via email: atulkavthekar@gmail.com

 

Dear Atul,

 

We are pleased to extend to you an offer of employment as Chief Financial
Officer of P3 Health Partners. We believe that all employees contribute directly to the Company’s growth and success, and we look
forward to you being a member of our team. Following are the terms of our offer of employment:

 

Position: Chief Financial Officer

 

Report To: Chief Executive Officer (currently Sherif Abdou,
MD, MMM, FACP, FACPE)

 

Annual Base Salary: $450,000

 

Start Date: December 12, 2022

 

Signing Bonus: We are pleased to offer you a signing bonus
of $50,000, to be paid within 15 days following the six-month anniversary of your Start Date (the “Signing Bonus”), subject
to your continued employment through such six-month anniversary. If you separate employment (voluntarily or involuntarily) from the Company
within one year following such six-month anniversary, you agree to repay a pro rata portion of the Signing Bonus.1

 

Benefits: During your employment, you will be eligible to participate
in all Company benefits, subject to the terms of the plan, program, or policy. Your health and wellness benefits are expected to begin
the first day of the month that occurs after 30 days following your Start Date. The benefits include a 401(k) plan.

 

 

1 The amount of repayment shall be the full amount of the
Signing Bonus multiplied by a fraction: the numerator of which is equal to the number of days you worked following such six-month anniversary,
and the denominator of which is 365.

 

     

     

    

 

Relocation: P3 offers relocation benefits to support your move
to Henderson. You will be reimbursed for reasonable expenses incurred by you, including up to two home finding trips, movement of household
goods up to $25,000, temporary housing for up to two months up to $12,000 in the aggregate, shipment of one automobile, and final move
expenses, all in accordance with the Company’s relocation reimbursement policy.

 

Travel: As an officer of the Company,
travel is required to attend meetings, engage with potential clients, develop relationships with physicians, clinical teams, etc. and
the overall build of the organization. You will be entitled to reimbursement for all reasonable and necessary out-of-pocket business
and travel expenses incurred by you in connection with the performance of your duties hereunder in accordance with the Company's expense
reimbursement policies and procedures.

 

Annual Incentive: During your employment, you will be eligible
to receive an annual performance bonus based on the achievement of the Company's and your target performance goals and metrics, established
by the Board of Directors (or a subcommittee thereof) each year, beginning with 2023. Your target bonus will be equal to 50% of your
base salary. You must be employed by the Company on the date an annual bonus is paid in order to receive the bonus.

 

One-Time Equity Grant: Subject to the approval of the Company’s
Board of Directors, P3 will grant you a non-qualified option to purchase 600,000 shares of P3’s Class A common stock (the “Stock
Option”). The Stock Option shall have an exercise price per share equal to the Fair Market Value on the grant date (as defined
in the 2021 P3 Health Partners Inc. Incentive Award Plan (the “Plan”)) and shall be subject to the terms and conditions applicable
to options granted under the Plan and a stock option agreement prescribed by the Company. You will vest in 25% of the Stock Option on
the first anniversary of your Start Date (the “Initial Vesting Date”), and the remaining 75% will vest in equal annual installments
over the following three years on each anniversary of the Initial Vesting Date, subject to your continued employment through the applicable
vesting date.

 

Severance: In the event your employment is terminated by the
Company without “cause” (as determined by the Company in its sole discretion, you will receive a lump sum payment equal to
six months of base salary at the annual rate of pay in effect on the date of termination (the “Severance Pay”), payable within
30 days following your termination date, subject to your timely execution and non-revocation of a general release of claims (in a form
prescribed by the Company) and your compliance with certain restrictive covenants, including non-competition and non-solicitation covenants.

 

Taxes: All payments to you under this letter will be subject
to any required withholding of federal, state and local taxes pursuant to any applicable law or regulation and the Company and its affiliates
are entitled to withholding any and all such taxes from mounts payable under this letter. No amount that is deferred compensation subject
to Section 409A of the Internal Revenue Code, as amended (the “Code”) shall be payable pursuant to this letter unless your
termination of employment constitutes a “separation from service” from the Company within the meaning of Section 409A of
the Code and the Department of Treasury regulations and other guidance promulgated thereunder (“Section 409A”). For purposes
of Section 409A, your right to receive any installment payments under this letter shall be treated as a right to receive a series of
separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment. Notwithstanding
the foregoing, no compensation or benefits, including without limitation any severance payments or benefits described above, shall be
paid to you during the six-month period following your “separation from service” from the Company if the Company determines
that paying such amounts at the time or times indicated in this letter would be a prohibited distribution under Section 409A(a)(2)(B)(i)
of the Code. If the payment of any such amounts is delayed as a result of the previous sentence, then on the first business day following
the end of such 6-month period (or such earlier date upon which such amount can be paid under Section 409A without resulting in a prohibited
distribution, including as a result of your death), the Company shall pay you a lump-sum amount equal to the cumulative amount that would
have otherwise been payable to you during such period.

 

     

     

    

 

This letter is designed to outline your offer of employment
and is contingent upon a final reference and passing the preemployment background and drug screening. Please signify by signing this
letter that you understand that employment with P3 shall be at-will, and either party will be free to end this relationship for any reason
or no reason.

 

We look forward to having you as part of our team here
at P3 Health Partners. Please return this signed letter.

 

If you have any questions or concerns about this letter,
please do not hesitate to contact me at (702) 910-3951. Please indicate your acceptance by signing and returning this document to me
as soon as possible, via scan or mail to 2370 Corporate Circle, Suite 300 Henderson, NV 89074.

 

	Sincerely,	 
	 	 
	/s/ Sherif Abdou, M.D.	 
	Sherif Abdou, MD, MMM, FACP, FACPE	 
	Chief Executive Officer	 

 

I agree to the terms stipulated and indicate my acceptance
by signing and returning this document via DocuSign.

 

	 	Date:	11/27/2022
	 	 	 
	 	Signed:	/s/ Atul Kavthekar

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]